Company Overview
About Cleancard
Cleancard is a United States-based at-home cancer screening company — backed by Y Combinator (S23) with $846,000 in total funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and the Creative Destruction Lab — developing a 30-minute at-home diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers from a single patient sample for prostate, bladder, and ovarian cancers. Founded by Luca Springer and Thomas Carroll (both Rhodes Scholars from Oxford), Cleancard targets the massive unmet need for accessible, affordable cancer screening outside of clinical settings — the 30-minute result time and home-based format enabling screening at the frequency and convenience required for early cancer detection programs.
Business Model & Competitive Advantage
Cleancard's at-home cancer screening technology addresses the access and adherence barriers that reduce the effectiveness of existing cancer screening programs: prostate-specific antigen (PSA) testing, bladder cancer urine cytology, and ovarian cancer CA-125 testing are all clinic-based procedures that require scheduling appointments, traveling to labs, and waiting days for results — friction that causes eligible patients to skip routine screening or delay follow-up after abnormal results. Cleancard's platform uses synthetic biology-engineered biosensors (designed to detect specific cancer biomarker proteins or genetic signatures in urine or blood samples) combined with computer vision analysis of the test result pattern (reading the quantitative biomarker level from the test strip or cartridge format) to deliver clinical-grade sensitivity and specificity in a consumer-facing format. The multiplexable format (detecting multiple cancer biomarkers from a single sample) enables panel testing that improves early detection probability compared to single-marker testing — a key advance over current single-analyte home tests. Mayo Clinic Platform's investment provides the clinical validation infrastructure and healthcare system distribution relationships that consumer diagnostic companies require for clinical adoption.
Competitive Landscape 2025–2026
In 2025, Cleancard competes in the at-home diagnostics, cancer screening, and consumer health testing market with Galleri (Illumina/GRAIL multi-cancer early detection liquid biopsy, $1.9B raised), Exact Sciences (NASDAQ: EXAS, Cologuard colorectal cancer screening, $1B revenue), and EarlySign (AI-based early cancer detection, $21M raised) for consumer and healthcare system early cancer detection platform adoption. Mayo Clinic Platform's partnership (Mayo Clinic is one of the world's most trusted healthcare institutions) provides clinical validation credibility critical for consumer cancer diagnostic adoption where clinical trust is paramount. Rhodes Scholar founding team backgrounds reflect the academic research rigor that translates synthetic biology biosensor research into manufacturable consumer diagnostic products. The 2025 strategy focuses on achieving clinical validation data for the prostate and bladder cancer panels, pursuing FDA 510(k) clearance for at-home use authorization, and building the telehealth follow-up pathway for patients with positive screening results.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Cleancard is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Compare Cleancard with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cleancard? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cleancard Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cleancard vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →